Phase II/III CRO Benchmarking—Small Pharma Market

Report Overview

Clinical outsourcing needs and perceptions can vary quite a bit by company. ISR understands the desire for a deeper dive regarding the small and emerging biopharma landscape. ISR’s CRO Quality Benchmarking – Phase II/III Service Providers: A Look at Small and Emerging Biopharma (2020) report does just that. This research will help small and emerging biopharma companies make more informed CRO selection decisions. These findings will also help CROs optimize operational and marketing strategies to better accommodate this segment. The degree of detail provided in this report — straight from small and emerging biopharma customers — on CRO awareness, familiarity, reported use, and preference along with perceived leadership, cost perceptions and CRO selection drivers offers a bird’s eye view into this segment.

This report was compiled with the small and emerging biopharma company in mind, and various comparisons are made to the larger Phase II/III outsourcing audience.

What you will learn:

Small & Emerging Sponsors:

• Make a more educated purchase of CRO services by understanding which providers best fit your company’s needs
• Uncover which CRO attributes drive outsourcing selection for Phase II/III clinical trials as well as which CRO attributes have gained importance over the past 12 months among industry peers
• Understand overall CRO customer loyalty via ratings of customer satisfaction, willingness to recommend, and likelihood to use again

Service Providers:

• Understand your company’s market awareness and positioning, and use this information to develop targeted messaging to small and emerging biopharma companies
• Gain insight into small and emerging biopharma preferences and practices with respect to CRO selection and CRO outsourcing preferences

Major Topics:

• Service Provider Selection Process
• Service Provider Perceptions and Interactions
• Study Data
• Demographics